A neuromuscular-focused cell and gene therapy startup leveraged investor intelligence mapping and competitive benchmarking to sharpen capital raising strategy.
Let's TalkThe client lacked a comprehensive view of which investors were actively backing neuromuscular disorder therapies and whether their pipeline aligned with current investor preferences. They relied on ad-hoc research, which obscured real-time funding trends.
While the client had strong early-stage data, they struggled to articulate how their therapeutic approach compared with competing platforms, in terms of mechanism, target indication focus and stage of development, making it difficult to justify funding pitches.
The client lacked a structured approach to identify optimal investor segments, understand deal parameters and forecast likely funding trajectory. This limited proactive capital raising and hindered board-level strategic planning.
